Also trades as: EYE.AX (ASX) · $vol 0M
ELXMF OTC
Nova Eye Medical Limited
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +653.2%
1Y: -85.7%
3Y: -85.7%
5Y: -94.5%
$0.01
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$35M
+19.0% ▲
5Y CAGR: +21.1%
Gross Profit
$25M
+32.2% ▲
5Y CAGR: +69.8%
Operating Income
-$4M
+3.0% ▲
Net Income
-$4M
+52.2% ▲
EPS (Diluted)
$-0.02
+58.5% ▲
EBITDA
-$2M
+67.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $13M | $17M | $23M | $29M | $35M |
| YoY Growth | -0.1% | +27.3% | +37.0% | +25.5% | +19.0% |
| Cost of Revenue | $14M | $16M | $3M | $10M | $10M |
| Gross Profit | -$765K | $842K | $20M | $19M | $25M |
| Gross Margin | -5.7% | 4.9% | 86.6% | 64.5% | 71.7% |
| R&D Expenses | $276K | $617K | $5M | $4M | $2M |
| SG&A Expenses | $12M | $14M | $15M | $20M | $27M |
| Operating Expenses | $9M | $13M | $29M | $23M | $29M |
| Operating Income | -$7M | -$12M | -$9M | -$5M | -$4M |
| Operating Margin | -49.2% | -69.6% | -38.4% | -15.4% | -12.5% |
| Interest Expense | $64K | $54K | $70K | $74K | $154K |
| Income Before Tax | -$8M | -$17M | -$9M | -$9M | -$4M |
| Tax Expense | -$750K | -$2M | $0 | $0 | $0 |
| Net Income | -$7M | -$15M | -$9M | -$9M | -$4M |
| Net Margin | -56.0% | -89.8% | -37.7% | -31.0% | -12.4% |
| EPS (Diluted) | $-0.05 | $-0.10 | $-0.04 | $-0.04 | $-0.02 |
| EBITDA | -$8M | -$9M | -$6M | -$7M | -$2M |
| Shares Outstanding | 149M | 160M | 204M | 247M | 285M |